What Is Ibogaine? The Biology,
Clearly Explained
Ibogaine is not easy to categorize. It is not an opioid, not a classic psychedelic, not an antidepressant — yet it interacts with all of those systems simultaneously. Understanding what it actually is, and what it actually does in the body, requires setting aside the familiar drug categories and looking at the biology directly.
This article does exactly that. It follows ibogaine from its source plant into the bloodstream, through the liver, across the blood-brain barrier, and into the receptor systems and neurotrophic cascades where its effects unfold. The goal is precision — not promotion.
Where Ibogaine Comes From
Ibogaine is an indole alkaloid extracted from the root bark of *Tabernanthe iboga*, a perennial shrub native to Gabon and the surrounding Central African rainforest. The plant has been used for centuries in the Bwiti spiritual tradition as a ceremonial sacrament, where it is consumed in structured ritual contexts under the guidance of experienced practitioners.
The ibogaine content of raw iboga root bark varies depending on the plant's age, growing conditions, and preparation — typically ranging between 1 and 5% by dry weight. This variability makes precise dosing with raw plant material clinically impractical. For treatment purposes, ibogaine is extracted, purified, and synthesized as ibogaine hydrochloride (ibogaine HCl), which can reach purities above 98%. This standardization is essential: therapeutic dosing is calculated by body weight, and consistency in the compound being administered is a baseline safety requirement.
How the Body Processes Ibogaine
Absorption and First-Pass Metabolism
Ibogaine is typically administered orally in capsule form. Once ingested, it is absorbed through the gastrointestinal tract into the bloodstream. On its first pass through the liver, ibogaine is metabolized primarily by the cytochrome P450 enzyme CYP2D6, which converts it to its principal active metabolite, noribogaine (also known as 12-hydroxyibogamine). This O-demethylation process begins quickly — noribogaine appears in blood plasma soon after oral ibogaine is consumed, confirming that first-pass hepatic metabolism is occurring.
The proportion of ibogaine converted to noribogaine on this first pass varies between individuals and is not precisely established in the peer-reviewed literature as a fixed percentage. What is established is that CYP2D6 activity varies significantly due to genetic differences. Approximately 5 to 10 percent of people of European descent are classified as "poor metabolizers" — they have reduced or absent CYP2D6 function, which means ibogaine is metabolized more slowly. In these individuals, the combined blood levels of ibogaine plus noribogaine can be approximately twice as high as in normal metabolizers. This has direct implications for dosing and safety, and is a reason why CYP2D6 genotyping is clinically relevant before treatment.
Ibogaine Is Lipophilic
Ibogaine is highly lipophilic — it accumulates in fat tissue. This property is pharmacologically significant: ibogaine redistributes from blood plasma into adipose tissue over time, which contributes to its complex pharmacokinetic profile and may play a role in its lipid-related metabolic effects.
Two Compounds, Two Time Courses
Once in circulation, both ibogaine and noribogaine cross the blood-brain barrier and exert pharmacological effects — but they do so over very different time horizons.
Ibogaine is short-acting. It is primarily responsible for the acute phase of the treatment experience, which typically begins 1 to 3 hours after ingestion and involves intense oneiric (dreamlike) states. This acute phase generally lasts 4 to 8 hours, after which an evaluative and integrative period follows as ibogaine blood levels decline.
Noribogaine has a substantially longer half-life, documented in clinical pharmacokinetic studies at 28 to 49 hours. This means it remains active in blood plasma for approximately two days after a single treatment. It is noribogaine's sustained presence — not ibogaine's — that is believed to drive the extended therapeutic window: the period of improved mood, reduced cravings, and neurochemical rebalancing that patients often report in the days and weeks following treatment.
The full arc of the treatment experience — acute, evaluative, and residual — spans roughly 36 to 72 hours, with most acute effects resolving within the first day. The claim that noribogaine remains detectable in the body for "weeks to months" significantly overstates what is established. Its documented half-life places plasma clearance within a matter of days for most individuals.
What Ibogaine and Noribogaine Do in the Brain
A Multi-Receptor Profile, Not a Single Mechanism
Both ibogaine and noribogaine bind to multiple receptor systems in the central nervous system. This is not a bug in the pharmacology — it is likely the source of ibogaine's distinctive effects. Researchers have described this as a "polypharmacy effect" or "matrix pharmacology": therapeutic outcomes that arise from synergistic action across several neural pathways simultaneously, rather than from a single targeted interaction.
The key receptor interactions are:
NMDA receptor antagonism. Ibogaine blocks NMDA (N-methyl-D-aspartate) glutamate receptors — the same receptor that ketamine targets. This disrupts excitotoxic signaling, reduces the reinforcement of compulsive neural patterns, and contributes to the visionary, introspective quality of the acute experience. NMDA blockade also promotes neuroplasticity by triggering downstream signaling pathways including mTOR.
Kappa and mu opioid receptor activity. Both ibogaine and noribogaine act at opioid receptors, with noribogaine showing greater potency at the kappa opioid receptor (KOR). Kappa opioid activity modulates the stress response, emotional processing, and compulsive behavior, and contributes to ibogaine's well-documented ability to interrupt opioid withdrawal. Noribogaine has been specifically characterized as a G-protein biased kappa opioid receptor agonist.
Serotonin transporter inhibition. Noribogaine is a potent inhibitor of the serotonin transporter (SERT), significantly more potent at SERT than at the dopamine transporter (DAT). In vivo microdialysis studies in rats confirm that noribogaine produces a marked, dose-related elevation in extracellular serotonin — an effect not seen with ibogaine alone at comparable doses. This sustained serotonergic activity is one mechanism behind post-treatment improvements in mood and emotional stability.
Dopamine transporter modulation. Both compounds interact with the dopamine transporter (DAT), but the clinical picture here requires precision. In vivo microdialysis research has shown that ibogaine does not produce meaningful elevations in extracellular dopamine in the nucleus accumbens, despite its DAT activity. The dopaminergic effects appear more indirect — mediated through GDNF upregulation and normalization of reward circuitry rather than direct dopamine release.
Nicotinic acetylcholine receptor inhibition. Ibogaine inhibits nicotinic acetylcholine receptors (nAChRs), particularly the alpha3-beta4 subtype. This has been proposed as a mechanism contributing to its anti-addictive effects on nicotine and stimulants, and may support cognitive function through effects on cholinergic signaling.
Sigma receptor activity. Ibogaine has affinity for sigma-1 and sigma-2 receptors, which are involved in neuroprotection, neuroplasticity, and the regulation of myelination. Sigma receptor activation may contribute to ibogaine's potential in neurological conditions including traumatic brain injury and multiple sclerosis.
The Neurotrophic Factor Cascade
Receptor activity is only part of the story. What makes ibogaine pharmacologically distinctive is what happens downstream: a cascade of neurotrophic factor expression that sets biological processes of repair and reorganization in motion.
GDNF: Protecting the Reward System
Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a protein critical to the survival and function of dopaminergic neurons — the neurons most directly implicated in addiction and reward. A single ibogaine administration has been shown to produce a dose-dependent increase in GDNF expression in the Ventral Tegmental Area (VTA) and Substantia Nigra — the midbrain regions that are the origin points of the dopaminergic mesocorticolimbic pathway. This GDNF upregulation persists well beyond the pharmacokinetic clearance of ibogaine itself, suggesting an autocrine amplification loop: GDNF, once elevated, continues to drive its own production. This mechanism is one of the leading candidates to explain ibogaine's lasting anti-addictive effects after a single treatment.
GDNF's relevance extends beyond addiction. Its neuroprotective role in dopaminergic neurons is precisely why ibogaine is being studied as a potential treatment in Parkinson's disease research.
BDNF: Rewiring for Plasticity
Brain-Derived Neurotrophic Factor (BDNF) is essential for learning, memory, synaptic development, and the structural plasticity of neural circuits. Ibogaine administration produces substantial, dose-dependent upregulation of BDNF expression across multiple brain regions 24 hours after treatment — including the Nucleus Accumbens, Prefrontal Cortex, VTA, and Substantia Nigra. The increases documented in preclinical research are large in magnitude.
It is important to clarify a common oversimplification: BDNF upregulation is not exclusively linked to noribogaine's serotonin transporter activity, nor GDNF exclusively to ibogaine's dopamine transporter activity. The research shows that both ibogaine and noribogaine contribute to upregulation of both BDNF and GDNF through overlapping and complementary pathways. The sustained serotonergic activity driven by noribogaine does enhance BDNF expression — this mechanism is well established — but GDNF induction also involves serotonergic pathways, and ibogaine's NMDA antagonism contributes to both neurotrophic cascades.
NGF: Supporting Cognitive Repair
Nerve Growth Factor (NGF) supports learning, memory consolidation, and neuronal repair, particularly in the cholinergic systems relevant to cognitive function. Ibogaine administration also modulates NGF expression, with significant upregulation observed 24 hours post-treatment in multiple brain regions. Its relevance is particularly notable in the context of traumatic brain injury and cognitive impairment associated with chronic substance use.
Neuroplasticity: What These Changes Actually Mean
Neuroplasticity is the brain's capacity to reorganize itself — forming new synaptic connections, modifying existing ones, generating new neurons in regions where adult neurogenesis remains active, and remodeling the architecture of functional circuits. These processes are not constant; they require the right biological conditions.
Noribogaine has been classified in the scientific literature as a "psychoplastogen" — a compound that rapidly promotes structural neural plasticity. In cultured rat cortical neurons, noribogaine promotes neuritogenesis (the growth of new neuronal projections), an effect comparable to what is observed with ketamine. This structural plasticity is likely mediated in part through the mTOR signaling pathway, which is activated downstream of BDNF binding to its receptor TrkB. Both noribogaine and ketamine promote structural and functional neuroplasticity through mechanisms that converge on mTOR.
Additionally, a single dose of noribogaine has been shown to promote structural plasticity by increasing dendritic branching complexity in rats — an effect that is blocked by ketanserin, a serotonin 2A receptor antagonist. This suggests that noribogaine's plasticity-promoting effects involve partial serotonin 2A receptor agonism, a property distinct from classical psychedelics that strongly activate this receptor but present in noribogaine at low-level affinity.
The net result of receptor activation, neurotrophic factor upregulation, and mTOR-mediated structural remodeling is a biological environment that genuinely supports circuit-level change. This is the mechanistic basis for describing ibogaine as a psychoplastogen — not a metaphor, but a description of measurable biological events.
Elimination
Ibogaine and noribogaine are ultimately broken down through hepatic metabolism and cleared primarily through renal excretion. Noribogaine's documented half-life of 28 to 49 hours means that for most individuals, plasma concentrations become negligible within several days. The quiet period of neurobiological consolidation following treatment — the days during which improved mood, emotional clarity, and reduced cravings are often reported — overlaps with noribogaine's extended presence in plasma and its downstream neurotrophic effects, which continue even as blood levels decline.
Frequently Asked Questions
Why is noribogaine considered more therapeutically important than ibogaine itself?
Ibogaine is short-acting and drives the acute experience. Noribogaine, with its half-life of 28 to 49 hours, sustains neurochemical activity long after the acute phase ends. Its potent serotonin transporter inhibition, kappa opioid receptor agonism, and ability to promote structural neuroplasticity are the primary mechanisms behind the extended therapeutic window — the days of mood improvement, reduced cravings, and neurobiological consolidation that follow treatment.
What does it mean that ibogaine is a "psychoplastogen"?
A psychoplastogen is a compound that rapidly promotes structural changes in the brain — specifically the growth of new neuronal projections and dendritic branches. Noribogaine meets this definition: in laboratory studies, it promotes neuritogenesis in cortical neurons and increases dendritic complexity in rats. These structural changes are believed to underlie the lasting cognitive and behavioral effects of treatment.
Does ibogaine work by releasing dopamine?
Not directly. Despite modulating the dopamine transporter, ibogaine does not produce meaningful increases in extracellular dopamine in vivo at therapeutic doses. Its effects on the dopaminergic system appear more indirect — primarily through GDNF upregulation in the VTA and Substantia Nigra, which protects and restores dopaminergic neurons rather than flooding them with dopamine.
Why does genetic variation in CYP2D6 matter for ibogaine treatment?
CYP2D6 is the enzyme responsible for metabolizing ibogaine to noribogaine. People with reduced CYP2D6 activity ("poor metabolizers") process ibogaine more slowly, resulting in higher combined blood levels of ibogaine and noribogaine. This increases both the intensity of effects and the cardiac safety risk. Genotyping for CYP2D6 status before treatment is a clinically meaningful step that informs appropriate dose selection.
How is ibogaine different from classic psychedelics like psilocybin or LSD?
Classical psychedelics act primarily through strong agonism at the 5-HT2A serotonin receptor. Ibogaine has very low affinity for this receptor and does not produce the head-twitch response in animal models that marks 5-HT2A activation. Its mechanism is categorically different: multi-receptor modulation across opioid, glutamatergic, serotonergic, cholinergic, and sigma receptor systems, combined with potent neurotrophic factor upregulation. The resulting experience — longer, more oneiric, and with a distinct quality of introspection — is qualitatively different from classical psychedelics.
Speak With Nomena's Clinical Team
At Nomena, based in Southeast Asia, our clinical approach is built around the same pharmacological reality described in this article. Ibogaine's multi-receptor pharmacology and neurotrophic effects require careful patient selection, preparation, and medical monitoring — not because the compound is dangerous in principle, but because its biological potency demands a rigorous clinical framework.
Every person we work with receives a thorough pre-treatment assessment including cardiac evaluation, medication review, and CYP2D6 metabolizer status where indicated. Treatment is conducted with continuous ECG monitoring and medical staff on-site throughout.
If you want to understand whether ibogaine treatment is appropriate for your specific situation — with accurate information and no pressure — we welcome that conversation.
Contact Nomena to speak with a member of our clinical team.
Citations
1. Marton S, González B, Rodríguez-Bottero S, et al. "Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits." Frontiers in Pharmacology, 2019.
2. Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL. "Identification of a Primary Metabolite of Ibogaine That Targets Serotonin Transporters and Elevates Serotonin." Life Sciences, 1995.
3. Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L. "Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability." The Journal of Clinical Pharmacology, 2015.
4. Glue P, Winter H, Garbe K, et al. "Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers." The Journal of Clinical Pharmacology, 2015.
5. Noller GE, Frampton CM, Yazar-Klosinski B. "Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study." The American Journal of Drug and Alcohol Abuse, 2018.
6. Ona G, Reverte I, Rossi GN, et al. "Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: a mechanistic overview." Journal of Psychopharmacology, 2023.
7. Ly C, Greb AC, Cameron LP, et al. "Psychedelics promote structural and functional neural plasticity." Cell Reports, 2018.
8. Maillet EL, Milon N, Heghinian MD, et al. "Noribogaine is a G-protein biased kappa-opioid receptor agonist." Neuropharmacology, 2015.
9. Govender N, et al. "Neurorestorative properties of ibogaine: linking multi-receptor affinities to remyelination and metabolic restoration." Neuropsychopharmacology Reports, 2026.
10. Cherian KN, Keynan JN, Anker L, et al. "Magnesium-ibogaine therapy in veterans with traumatic brain injuries." Nature Medicine, 2024.